Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

17.59 USD -0.53 (-2.92%)
Streaming Delayed Price Updated: 3:16 PM EST, Jan 18, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,403,759
Open 18.24
Bid (Size) 17.59 (4)
Ask (Size) 17.60 (10)
Prev. Close 18.12
Today's Range 17.59 - 18.24
52wk Range 15.50 - 25.77
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Tenaya Therapeutics Provides 2022 Business Updates
Tenaya Therapeutics provided a 2022 business update. 
From Business Wire News Releases
Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022
Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fourth quarter and full year 2021, provided financial guidance for full year 2022, and delivered an... 
From Business Wire News Releases

Performance

YTD
-8.29%
-8.29%
1 Month
-5.13%
-5.13%
3 Month
-17.46%
-17.46%
6 Month
+7.91%
+7.91%
1 Year
-25.43%
-25.43%

More News

Read More
Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor
From Business Wire News Releases
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma
From Business Wire News Releases
Exelixis to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022
From Business Wire News Releases
Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
From Business Wire News Releases
Analysts Expect MDYV Will Reach $83
Tags ETFs
From ETF Channel
Exelixis Elects Jacqueline Wright to Its Board of Directors
From Business Wire News Releases
A Peek Into The Markets: US Stock Futures Edge Higher; Crude Oil Up 0.5%
Tags Pre/Market Outlook TSLA TKAT
From Benzinga
Exelixis Announces Initiation of Phase 1b Trial Evaluating XL092 in Combination with Immuno-oncology Therapies in Patients with Advanced Solid Tumors
From Business Wire News Releases
3 Biotech Stocks Wall Street Thinks Could Soar 50% or More in 2022
Tags BMY Market News EXEL
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.